

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12th August, 2021

Corporate Relationship Department M/s .BSE Ltd. Dalal Street, Fort <u>Mumbai – 400 001</u>.

The Manager – Listing M/s.National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra(E), <u>MUMBAI – 400 051</u>.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

- Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2021 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed a copy of the same.
- Declared interim dividend of Rs.2/- (Rupees Two only) (100%) each per equity share of Rs.2/-(Rupees two only) each for the financial year 2021-22. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as Wednesday the 25th day of August, 2021. The payment of said interim dividend will be paid from 31st August 2021.

We are also updating the financial results on the website of the Company.

Please find enclosed press release on Q1 FY 2021-22 results.

Meeting commenced at 10.45 a.m. and concluded at 1.00 p.m.

This is for your information.

Thanking you

Yours faithfully, For NATCO Pharma Limited MAna Sayanud

M Adinarayana Company Secretary & Vice President (Legal & Corp Affairs)

Encl: as above